Modality
Cell Therapy
MOA
CAR-T BCMA
Target
GIP-R
Pathway
JAK/STAT
SCLC
Development Pipeline
Preclinical
~Feb 2017
→ ~May 2018
Phase 1
~Aug 2018
→ ~Nov 2019
Phase 2
~Feb 2020
→ ~May 2021
Phase 3
~Aug 2021
→ ~Nov 2022
NDA/BLA
Feb 2023
→ Sep 2028
NDA/BLACurrent
NCT04428727
1,176 pts·SCLC
2023-02→2028-09·Terminated
1,176 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-09-262.5y awayPh3 Readout· SCLC
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2028-09-26 · 2.5y away
SCLC
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04428727 | NDA/BLA | SCLC | Terminated | 1176 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R |